Anagenics Limited · ASX:AN1
Anagenics — Investor Presentation (February 2023)
27 slides from Anagenics's investor presentation, Feb 14, 2023
Slide 1: Building on turnaround with a growing beauty & wellness portfolio
For personal use only ASX: AN1 Building on turnaround with a growing beauty & wellness portfolio Equity Capital Raising Presentation * NOT FOR RELEASE TO US WIRE SERVICES OR DISTRIBUTION IN THE UNITED STATES 2023
Slide 2: AN1 – Disclaimers
AN1 – Disclaimers For personal use only This presentation (including the appendices, any ancillary documents relating to it, any oral presentation and any question or answer session) (‘Presentation’) is dated 14 February 2023 and has been prepared by Anagenics Limited (ACN 111 304 119) (‘Company’, ‘
Slide 3: AN1 – Disclaimers
AN1 – Disclaimers For personal use only Past performance Any past performance information, including past price performance of the Company’s shares and financial information given in this Presentation, is given for illustrative purposes only and should not be relied upon as (and is not) an indicatio
Slide 4: What is Anagenics?
What is Anagenics? A growing portfolio serving global markets For personal use only Underpinned by profitable, trusted, and validated leading brands 1,000 PARTNERSHIPS AN1 FY22¹ 55% Gross Margin Accounts across ANZ USA CHINA $10m Total Revenue +47% on PY 26 employees ANZ 13 Brands distributor ADDITI
Slide 5: How have we evolved?
How have we evolved? From solo product to diversified range For personal use only 2002 - 2020 2021 2022 Since 2002 CREATING IP MAJOR ACQUISITION RESETTING TO SCALE we have expanded our portfolio to provide holistic solutions, developing an international reputation as a 2005 NOVEMBER JULY Medical The
Slide 6: How is Anagenics performing?
How is Anagenics performing? Evidence of success with acquisition For personal use only FY23 | SUCCESS INDICATORS REVENUE – $'000¹ BLC EBITDA – $'000 (underlying) Revenue - Total BLC EBITDA - $ Growing Revenue - BLC 400 BLC EBITDA - % of Revenue 16% post-acquisition 15% 350 13% 14% Record 3,899 300
Slide 7: Where are the cost benefits?
Where are the cost benefits? Streamlining to For personal use only maximise future returns Labour and operational costs STAFF COSTS ADVERTISING & PROMOTION OTHER OVERHEADS TOTAL SAVINGS % of revenue % of revenue % of revenue 69% $1.1m 90% 20% FY23 YTD cost out savings 15% 15% 59% 13% incl. Japan d
Slide 8: Building a platform for growth
Building a platform for growth Trusted, science-based solutions that deliver results For personal use only People Technology Network Products Driven by an experienced Continued development Connect ANZ professional Scientifically-validated, leadership team with a track of patented technology channel
Slide 9: What is our plan for success?
What is our plan for success? Building a competitive portfolio to drive growth For personal use only ENHANCE E-COMMERCE PROFITABILITY PROFIT FROM MERGERS AND ACQUISITIONS INNOVATE TO GROW ORGANICALLY Streamlined and simplified platforms Strengthened portfolio with trusted brands Continued competitiv
Slide 10: How will we leverage the opportunity?
How will we leverage the opportunity? Our Strategic Initiatives For personal use only Anagenics is working to accelerate: • Streamlining and simplifying platforms • Creating value through M&A • Innovating to remain competitive Invest in developing Proactively source M&A Re-platform Expand innovation
Slide 11: What experience is behind Anagenics?
What experience is behind Anagenics? For personal use only Alison Navarrete | Head of Marketing Matthew Dudek | CEO Dr Martin Cross | Non-Exec. Director Seasoned beauty industry marketer Strategic, financial and commercial experience Senior commercial pharmaceutical, and brand strategist spanning co
Slide 12: Offer Details
For personal use only ASX: AN1 Offer Details Equity Capital Raising Presentation 12
Slide 13: Offer Details - Overview
Offer Details - Overview $3.2m fully underwritten Entitlement Offer For personal use only Equity raising Institutional Director commitments size and structure Offer price Entitlement Offer1 Retail Entitlement Offer1 Fully underwritten pro rata All New Shares under the The institutional component • T
Slide 14: Intended use of funds
Offer Details Intended use of funds For personal use only Following streamlining of the AN1 business with growing revenue and earnings driven by BLC, the Entitlement Offer will facilitate the next leg of growth through synergistic M&A and profitable organic initiatives. CAPITAL INITIATIVES & CAPITAL
Slide 15: 2023 Indicative Timetable
Offer Details 2023 Indicative Timetable For personal use only FEBRUARY EVENT MARCH EVENT Announcement of the Entitlement Offer 6 Monday Retail Entitlement Offer closes (5.00pm Sydney time) 14 Tuesday Institutional Entitlement Offer opens 8 Wednesday Announcement of results of Retail Entitlement Offe
Slide 16: Pro Forma Capital Structure
Offer Details Pro Forma Capital Structure For personal use only CAPITAL STRUCTURE Current Free Shares on Issue1 Total Shares on issue1 Market cap (pre offer)2, 6 Rights Offer Shares to be issued3,4,5 188,234,418 221,266,401 $4,978,494 144,355,072 Restricted Shares on issue1 Shares on Issue (post off
Slide 17: Unlock growth opportunities with Anagenics
Unlock growth opportunities For personal use only with Anagenics Contact us today to find out how you can leverage the opportunity Anagenics Limited Suite 204, Level 2 Authorised for release to the ASX by Independent Board Committee 55 Clarence Street Sydney, NSW, 2000 Sandy Beard Matthew Dudek Scot
Slide 18: Statement of financial performance and balance sheet
For personal use only 1HF23 1HF22 31-Dec-22 30-Jun-22 STATEMENT OF FINANCIAL PERFORMANCE $'000 $'000 BALANCE SHEET $'000 $'000 FY23 Cash 2,099 3,285 Revenue from customers 5,355 4,177 Trade receivables 1,028 828 Cost of sales (2,701) (1,827) Inventories 2,553 4,448 Gross Profit 2,654 2,350 Other cur
Slide 19: Key Risks
Key Risks For personal use only This section discusses some of the key risks associated with any investment in Anagenics which may affect the value of its shares. The risks set out below are not listed in order of importance and do not constitute an exhaustive list of all risks involved with an inve
Slide 20: Key Risks
Key Risks For personal use only Control risk As at the date of this Presentation, the Underwriter has a relevant interest in approximately 17.36% of the ordinary shares in Anagenics. The number of New Shares that will be required to be taken up by the Underwriter, and therefore the increase in its r
Slide 21: Key Risks
Key Risks For personal use only SPECIFIC INVESTMENT RISKS Future capital needs and additional Anagenics recorded a net loss of $4,368,092 for the year ended 30 June 2022, and had a net cash outflow of approximately $1,186,000 for the half-year ending 31 December 2022. As at 31 December 2022, it fund
Slide 22: Key Risks
Key Risks For personal use only IP risk Anagenics’ ability to leverage its innovation and expertise depends upon its ability to protect its intellectual property and any improvements to it, as well as its confidential information. Intellectual property that is important to Anagenics includes, but is
Slide 23: Key Risks
Key Risks For personal use only Speculative nature of investment Any potential investor should be aware that subscribing for New Shares involves various risks. The New Shares to be issued pursuant to the Entitlement Offer carry no guarantees with respect to the payment of dividends, return of capita
Slide 24: Underwriting Agreement Summary
Underwriting Agreement Summary For personal use only Anagenics has appointed Hancock & Gore Limited (ACN 009 657 961) (‘HNG’) (the ‘Underwriter’) to fully underwrite the Entitlement Offer pursuant to an underwriting agreement entered into between the parties on or before the date of this announcemen
Slide 25: Underwriting Agreement Summary
Underwriting Agreement Summary For personal use only • any certificate which is required to be furnished by Anagenics to the Underwriter is not furnished when required; • Anagenics is insolvent, or there is an act or omission, or circumstance that arises, which is likely to result in Anagenics becom
Slide 26: Underwriting Agreement Summary
Underwriting Agreement Summary For personal use only • any adverse change, or an event that is likely to result in an adverse change, occurs in the assets, liabilities, financial position or performance, profits, losses or prospects of Anagenics from those respectively disclosed in any Offer Materia
Slide 27: International Offer Restrictions
International Offer Restrictions For personal use only This document does not constitute an offer of new ordinary shares (‘New Shares’) of Anagenics in any jurisdiction in which it would be unlawful. In particular, this document may not be distributed to any person, and the New Shares may not be off